We investigated vasoactive intestinal peptide (VIP)-receptor pharmacology in failing and
. The majority of immunoreactive material is found in atria; much smaller amounts are present in ventricular myocardium. 6 VIP mediates physiological effects through VIPspecific membrane receptors that are coupled to adenylate cyclase in myocardial membranes. 7 Failing human ventricular myocardium is characterized by selective ^-receptor down-regulation 8 and partial uncoupling of /^-receptors from adenylate cyclase. 9 Failing ventricular myocardium is also subsensitive to ^-agonist stimulation of adenylate cyclase and muscle contraction. 8 -9 In contrast, we have reported that the failing human heart is supersensitive to VIP stimulation of adenylate cyclase.
The purpose of the current investigation was to determine the mechanism for this VIP-mediated supersensitivity response by directly measuring VIP receptors and VIP-mediated muscle contraction responses in preparations derived from nonfailing and failing human ventricular myocardium.
Materials and Methods

Cardiac Tissue Procurement
Human cardiac tissue was obtained from the Utah and Stanford cardiac transplant programs. Ventricles of explanted hearts removed from heart transplant recipients were used as sources of failing heart; hearts from prospective donors not used for transplant and the left ventricles of heart-lung transplant recipients were used as nonfailing controls. Myocardial membranes were prepared from 13 severely failing (average cardiac index, 2.1 ±0.2 1/min/m 2 ; mean pulmonary wedge pressure, 19.8±2.7 mm Hg; mean right atrial pressure, 6.5±1.6 mm Hg; all values are mean±SEM) left ventricles explanted from patients with end-stage biventricular failure secondary to idiopathic dilated cardiomyopathy of whom none had received /3-receptor agonist infusions before transplantation and from six nonfailing hearts from organ donors with normal cardiac function by history and/or by echocardiogram. The hearts from the donors were not used for transplantation because of late-developing recipient exclusions, because of recipient blood type or size mismatch, or in two cases, because of age exclusion. In all cases, repeated attempts were made to place these hearts for organ donation through the United Network for Organ Sharing. Three additional nonfailing left ventricles were from heart-lung recipients with primary pulmonary hypertension and normal left ventricular function by echocardiogram.
Medications taken by all subjects with biventricular failure included diuretics and vasodilators, and two were also taking digoxin. Subjects with primary pulmonary hypertension were all taking diuretics, with two taking vasodilators and one taking digoxin. 
Myocardial Membrane Preparations
Crude myocardial membrane preparations suitable for VIP-and ^-receptor-binding studies were made as previously described. 9 -11 Briefly, 5-g aliquots of left ventricular free wall were minced in 10 volumes of a solution containing ice-cold 10 mM Tris and 1 mM EGTA (pH 8.0) and then homogenized with a polytron (three bursts for 5 seconds each). An equal volume of ice-cold 1 M KC1 was added and stirred for 15 minutes. The preparation was centrifuged at 50,00Q*f for 15 minutes; then the pellet was resuspended in a solution of 75 mM Tris and 10 mM MgCl 2 (pH 7.5). After two more centrifugations and a resuspension, the final pellet was suspended in a solution of 250 mM sucrose, 50 mM Tris buffer, and 1 mM EGTA (pH 7.5) to give a final protein concentration of 5-8 mg/ml. This preparation was frozen at -80° C until used.
Crude particulate preparations suitable for measuring adenylate cyclase activity were made from a 2-g aliquot of left ventricular free wall, as previously described. 9 For competition binding experiments, the final assay conditions were the same as those for saturation binding assays, except that a fixed concentration of radioligand (1 nM) was used to yield occupancy of approximately the same number of highand low-affinity binding sites.
j3-receptor saturation binding assays were performed, as previously described, 8 with [
I]iodocyanopindoiol (ICYP).
Adenylate Cyclase
Adenylate cyclase assays were performed by a radioenzymatic technique with previously described methods. 9 -11 Tissue Bath Studies Isolated right ventricular trabeculae were used to measure contractile response of human ventricular myocardium to VIP, isoproterenol, and calcium with previously described methods.
11 - 13 Trabeculae from 20 failing and eight nonfailing right ventricles were dissected into uniform strips of 1-2 mm x 6.0-7.0 mm and mounted in a plastic multichamber tissue bath maintained at 37° C. The isolated tissues were bathed in physiological salt solution (Tyrode's buffer (mM): NaCl 118, KC14, MgSO 4 1.2, NaHCO 3 25, NaH 2 PO 4 1.2, dextrose 5, and CaCl 2 2) bubbled with 95% O 2 -5% CO 2 to give a pH of 7.4. The isolated trabeculae were placed at a resting tension that yielded maximum contractile response, usually of approximately 1 g tension. Trabeculae were fieldstimulated at 5-10% above threshold voltage at 1 Hz with a 5-msec pulse wave delivered with platinum electrodes. Trabeculae were attached to stationary force transducers, and isometric developed tension was recorded with a calibrated strip chart recorder. Agonists were added in cumulative doses.
For studies with VIP, BSA was added to each bath to give a final concentration of 0.1%. BSA alone did not alter the tension responses. In three preliminary experiments, a further increase in inotropic effect was not found with concentrations of VIP greater than 1 ju,M, and because of the substantial expense of using VIP in concentrations greater than 1 ixM, this concentration was considered maximal response. VIP was added to baths at 8-minute intervals; isoproterenol was added at 2-minute intervals. At the completion of other pharmacological studies, the inotropic response to 10 mM calcium chloride was measured.
Creatine Kinase
Creatine kinase activity was measured in the supernatants of adenylate cyclase preparations, as previously described.
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Materials
Synthetic VIP (>99% peptide purity by highperformance liquid chromatography) was purchased from Bachem, Torrance, California. 
Data and Statistical Analyses
Receptor binding data. VIP receptor maximum binding estimates (B^, and B,,,^) and dissociation constants (K ai and K&) were determined by nonlinear least-squares computer modeling for the best fit of the specific binding curve (total binding less nonspecific binding), with the dependent variable bound counts per minute and the independent variable counts per minute of free [ [^IJVTP competition binding data were analyzed with CDATA, a part of the BDATA package, for the best fit of a two-site model.
-Receptor B^ and K d were determined by nonlinear least-squares computer modeling for the best fit of the specific binding curve as previously described. 8 Receptor density and K d were compared in the two groups by nonpaired Student's t test. A/J<0.05 in the two-tailed distribution was considered statistically significant.
Tissue bath data. Data were expressed as milligrams tension developed above basal tension. For experiments in which full VIP (13 experiments) and isoproterenol (12 experiments) dose-response curves were performed, the tension responses of all trabeculae that received VIP or isoproterenol were averaged together. Dose-response curves were modeled to a four-parameter logistic equation of DeLean et al 16 to find the best fit of a sigmoidal curve, including minimum, maximum, EDso, and slope. For VIP dose-response curves, the maximum developed tension (value at 1 fiM) was assigned to 10 JJLM and 100 /AM concentrations in order to enhance curve fitting because the expense of synthetic VIP prohibited routine use of higher concentrations than 1 p i M and preliminary experiments demonstrated no additional inotropic effect beyond this concentration.
Individual VIP and isoproterenol dose-response curve EDsoS, slopes, and maxima were compared in failing and nonfailing groups by a nonpaired Student's / test. Additionally, entire dose-response curves were compared in the failing and nonfailing groups by an analysis of covariance, as previously described. 9 
Results
Characterization of VIP Receptor Binding
The time course and effects of temperature on VIP binding are shown in Figure 1 . In this initial experiment, the 22° C isotherm was only extended to 80 minutes, but in four additional experiments that were extended to 120 minutes and one experiment that was extended to 240 minutes, specific Figure 2 . Because of the range of VIP concentrations necessary to occupy both the highand low-affinity binding sites, the data are divided into two different ranges. The entire data set is presented as a Scatchard plot in Figure 3 ; it can be seen that the plot is curvilinear and upwardly concave, consistent with two classes of binding sites.
Saturation binding assays were performed on myocardial membrane preparations from nine failing and nine nonfailing left ventricles (LVs). Each experiment was designed such that preparations from both failing and nonfailing ventricles were measured in the same assay. As can be seen in Table 1 , BDATA and LIGAND data analyses yield similar results, with the high-affinity VIP K 6 value being approximately 49% lower in the failing group. Likewise, the high-affinity B,,^ in failing LVs was approximately 40% (36.8% and 38.7%, respectively) of the value in nonfailing LVs. For the low-affinity site, no differences between failing and nonfailing LVs were found for either the Ka or the B max values.
During the characterization of the VIP receptor binding assay, we also performed competition curves between [ 123 I]VIP and unlabeled VIP to assess the reliability of the K 6 measured by saturation binding assays. A representative experiment is presented in Figure 4 ; this is the same preparation of failing LV used for the saturation binding curves shown in Figure 3 . The /Qs of 165 pM versus 226 pM and 27.9 nM versus 26.6 nM at the high-and low-affinity binding sites, respectively, represent reasonable agreement of K^ values for these two types of experiments.
Guanine nucleotides may modulate receptor affinity for agonists, 17 and for adenylate cyclasecoupled receptors, such modulation suggests the presence of a "physiological" binding site, that is, a receptor coupled to a signal transduction pathway. To determine if the two VIP binding sites are modulated by guanine nucleotides, we examined the effects of increasing concentrations of the nonhydrolyzable guanine nucleotide GppNHp on 4 fmol/mg). For the three experiments, the mean±SEM values for the high-affinity K^ shift were from 380±236 pM in the absence of GppNHp to 2,120 ±1,500 pM in the presence of GppNHp. Under both conditions, a two-site fit was superior to a one-site fit in all cases Q?<0.001 by F test, as described above). 
-Receptor Binding Data in Nonfailing and
Myocardial Membrane Markers
Adenylate cyclase activity in the presence of 10 mM sodium fluoride was not different between failing (n=7) and nonfailing (n=9) preparations (respective values of 37.06±3.14 vs. 41.38±4.83 pmol cyclic AMP/min/mg,/»=NS). Soluble creatine kinase activity likewise was not different between failing and nonfailing heart (respective values of 961 + 127 vs. 1,153±117 IU/g, p=NS).
Tissue Bath Data
VIP muscle bath data were compiled in two data sets because 13 initial experiments were performed with either one or three concentrations of VIP, and the subsequent 15 experiments consisted of ninepoint VIP dose-response curves. The first data set includes the responses of trabeculae from all 28 hearts exposed to 10 nM, 100 nM, and 1 jiM VIP concentrations. These data are summarized in Table   21700 2, along with maximum contractile responses for isoproterenol and calcium. The VIP data are also shown graphically in Figure 6 , where data inspection reveals two general findings. First, in failing heart, contractile response at the highest concentration of VIP is markedly decreased (810± 129.6 vs. 313±44.1 mg, /?<0.001), whereas contractile response at the lowest concentration of VIP demonstrates a twofold increase (179±24.6 vs. 101 ±21.0 mg, /?<0.02). Second, the apparent slopes of these "three-point dose-response curves" are very different with the responses from failing heart demonstrating a lower slope. In an attempt to obtain further quantitation of these apparent differences, we performed additional experiments evaluating a complete range of VIP concentrations between 10~1 The results of these nine-point VIP doseresponse curves compared with their corresponding isoproterenol dose-response curves are summarized in Table 3 Table 2 , in the smaller data set of fewer dose-response curves, this difference was not statistically significant (p=0.08).
Isoproterenol maximal tension responses, as given in Table 2 and Figure 8 , were likewise decreased in failing versus nonfailing trabeculae (985± 103.2 vs. 2,070±331.5 mg, p<0.005). In contrast, maximum inotropic effect of 10 mM calcium chloride (in 61 trabeculae from eight nonfailing and 120 trabeculae from 16 failing right ventricles) gave no difference (1,590+122.4 vs. 1,286± 103.2 mg,p=NS).
In contrast to left-shifted (supersensitive) EDJQS derived for VIP augmented muscle contraction data in failing heart, the average isoproterenol doseresponse curve EDso from these same hearts was right-shifted by 2.4-fold (ED 50 xl0~8 M isoproterenol: 2.91+0.556 vs. 1.23+0.169,/?<0.02, failing vs. nonfailing), as shown in Table 3 . The maximal isoproterenol tension was reduced in the failing hearts (l,018±225.5 vs. 2,173±266.7 mg,p<0.01), also in agreement with the larger data set given in Table 2 .
To better appreciate the quantitative differences in ED50S, individual VIP and isoproterenol doseresponse curves were also normalized to their own maximal responses and then averaged together to give "percent maximal" dose-response curves, as shows m Figures 7 and 8 . The VIP dose-response curves from failing heart are left-shifted by approximately twofold in agreement with the average of individual EDs, as presented in Table 3 . Likewise, average and percent maximal isoproterenol doseresponse curves from failing heart mar kby approximately 1.5-2-fold, both in close agree- ment with the average of individual dose-response curve data given in Table 3 .
Discussion
In the current investigation, the pharmacology of VTP in failing and nonfailing human ventricular myocardium was examined by receptor binding and muscle contraction studies. [ 125 I]VTP receptor binding revealed biphasic, upwardly concave, curvilinear Scatchard plots that could be resob/ed into high-(K^, 400-800 pM) and low-affinity (IQ, 50-100 nM) binding sites, consistent with what has previously been described for the VIP receptor in other tissues.
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The high-affinity binding site could be regulated by guanine nucleotides, which is consistent with what would be expected for a G-protein-coupled "physiological" agonist binding site. 17 These observations are in agreement with previous findings of the significance of high-and low-affinity VIP binding sites in other tissues. 18 -19 In contrast, agonist binding to the low-affinity site was not affected by guanine nucleotides. This occurrence suggests that this site may not be biologically active.
[^IJVTP binding in membrane preparations derived from failing human left ventricle demonstrated a twofold decrease in K^ (a twofold increase in affinity) compared with preparations derived from nonfailing heart. Additionally, a 62% decrease in VIP maximum binding or receptor density was present in failing heart. The decreased VTP receptor density observed in failing heart follows the precedent of decreased y3 r receptor density, 8 whereas the observation of decreased VTP receptor K A or increased receptor affinity is a novel finding for adenylate cyclase-coupled receptors in failing human heart. The dual observations of decreased density and increased affinity were surprising because these two alterations may give functional effects that oppose one another. That is, a decrease in receptor density may lead to a subsensitive response, whereas an increase in receptor affinity may lead to a supersensitive response. Furthermore, these observations were initially of some concern because the presence of the high-capacity (96% of the total), low-affinity VIP binding site creates the potential for erroneous resolution of the high-affinity portion of biphasic binding curves, 21 especially since the K d and B^, both decreased in preparations derived from failing heart. To provide assurance that these alterations were not simply a system artifact, the binding curves were analyzed by two different nonlinearregression curve-fitting computer programs that use different methods for determining the best fit, and the data from each type of analysis were in close agreement. Moreover, it was possible to observe and quantitate an effect of guanine nucleotides on the K d of the high-affinity, low-capacity VIP binding site. This observation provided further support for the contention that the heart failureassociated changes in VTP receptor affinity was truly biologic. However, the best support for the contention that the radioligand-measured differences in VIP receptor affinity and density were biologic phenomena present in failing heart was the directional concordance of the muscle bath data.
The VTP-mediated muscle contraction responses were in close agreement with the binding data: maximal contractile force was decreased by 62% in failing heart compared with a 61% decrease in VIP receptor density. Also, VTP dose-response curve position was left-shifted in failing heart by approximately twofold to threefold, in agreement with the twofold increase in VTP receptor affinity measured directly at [ In contrast to VIP muscle contraction data, isoproterenol dose-response curves in failing heart demonstrated a right-shifted EDjo as well as a decreased maximal response, the latter in agreement with earlier reports. 8 -11 These observations suggest that some degree of affinity change of Figure  6 , the response in failing heart is markedly decreased at higher concentrations of VIP, but at lower concentrations, failing heart gave increased contractile response. whereas ft-receptors partially uncouple in the failing human heart, 9 and it may be that one or both also demonstrate an agonist affinity shift to a lower, but still coupled, affinity state. At any rate, the right shift in the isoproterenol dose-response curves in failing preparations is in marked contrast to the left shift in VIP dose-response curves.
In an attempt to evaluate the VIP and /3-adrenergic receptor pathways beyond the receptor, 10 mM calcium chloride was routinely applied to all trabeculae at the end of muscle bath studies, and maximal teasiofl was aeasared. The tension response to maximal concentrations of calcium, which presumably acts independently of receptor function, was not different in right ventricular trabeculae removed from failing and nonfailing heart in this or in previous investigations by us 13 or by others.
skolin in isolated tissue preparations have not been different in failing and nonfailing heart. 21 Taken together, these findings suggest that the differences observed between failing and nonfailing heart for the VIP and j3-adrenergic pathways are caused by changes at the receptor level.
Although the decrease in VIP and /3-receptor density in failing human heart could have been an artifact of diseased or damaged tissue, flouridestimulated adenylate cyclase as a membrane marker and creatine kinase as a marker of viable myocardium were not different in tissue removed from failing ventricles compared with nonfailing controls. Moreover, previous studies in membranes extracted from failing human ventricular myocardium have shown that a variety of membrane markers are unchanged compared with nonfailing controls. 8 Thus, the changes in VIP and ^-receptor density present in membranes derived from failing myocardium are likely to be pharmacologically specific abnormalities rather than being secondary to "nonspecific" membrane dysfunction. Although medications such as digitalis, diuretics, and vasodilators taken by patients before cardiac transplantation could have had an effect on VIP receptors, no direct interaction of any of these agents with the VEP receptor is known.
In this series of investigations, right ventricular trabeculae were used to assess inotropic responses because they are more suited to quantitative pharmacological study than are left ventricular preparations. Although biochemical and binding data were measured in left ventricular preparations, right and left ventricular function was similar within respective classes of cardiac function. Moreover, we have previously shown that in left and right human ventricle, ^-receptor behavior is identical, provided that the functional status is similar. 8 ' 11 Thus, it is likely that the muscle-contraction behavior of right ventricular trabeculae was representative of both right and left ventricular tissue.
We observed functional ED50S of VlP-augmented muscle contraction in the 10+ nM range, whereas the agonist ED50S measured directly by [^IJVIP binding were in the 0.4-0.8 nM range. Similarly, the agonist K A , measured for ^-receptors, is in the 1-2 nM range, 22 yet the agonist ED^ for muscle contraction is 10-30 nM. Differences such as these between agonist-binding-determined K d s, and physiological-response EDJOS are not unusual when working with isolated tissue preparations. Multiple factors may explain these differences, including a nonlinear receptor-occupancy response relation 23 or a barrier to drug diffusion into trabeculae in whole-tissue preparations. We also observed that without the addition of BSA to decrease the nonspecific binding to the walls of the tissue baths, the contractile responses to VtP were markedly diminished or absent. As with many peptides, VIP will bind nonspecifically to glass and plastics, and the large surface areas of our 80-ml plastic tissue baths may bind a substantial amount of VIP despite the measures taken to minimize, this problem. This study has not addressed possible mechanisms accounting for VIP receptor regulatory changes in failing heart. Possible explanations include changes in tissue VIP levels derived locally from cardiac neural tissue or changes in circulating VIP. With regard to the latter, changes in circulating cardiac 24 and noncardiac 25 peptide hormones do occur in heart failure and are related to compensatory processes accompanying this clinical syndrome.
Alternatively, the change in the VIP receptor to a higher-affinity state could have been a primary compensatory change. If this were true, this change may lead to enhanced cardiac cell binding of VIP, which would initially provide inotropic support to the failing heart but which might ultimately be followed by receptor down-regulation. We have recently shown in a model system that both isoproterenol and VIP caused homologous desensitization of myocardial responses. 26 That is, exposure to VLP caused rapid desensitization of myocardial contractile response with no evidence of a supersensitivity response (a left shift in dose-response curve). 26 Heterologous desensitization of VIP receptors by ^-receptor agonists was not observed in this study. 26 On the other hand, altered VIP receptor density and affinity have recently been described in lung tissue after perturbations or certain membrane phospholipids. 19 It is also possible that the VIP receptor density and affinity changes are not causally related but that they may be independent events related temporally in the progression of myocardial failure. Prospective studies in human subjects with heart failure should help to resolve these issues.
It is not clear at this time if the VIP receptor alterations identified in this report have any relation to the pathogenesis or clinical course of human heart failure. However, of G,-coupled receptors, only /3-adrenergic (markedly decreased /3, density 8 and mild uncoupling of ft receptors 9 ) and VIP receptors (decreased density, increased affinity) have demonstrated alterations in failing human ventricular myocardium. In contrast, multiple receptors 27 -29 or receptor pathways 12 -30 in failing human ventricular myocardium are apparently not altered, including the H 2 histamine receptor pathway, 12 -27 the apreceptor, 28 the A! adenosine receptor pathway, 30 and the calcium channel-dihydropyridine receptor. The lack of alteration of these multiple receptors in failing human heart suggests that generalized or nonspecific panreceptor processes probably do not occur. Furthermore, the observed change in the /3 r receptor appears to be a relatively specific pharmacological response in failing human heart, and by inference the VIP receptor alterations may also be pharmacologically specific responses. Such specificity may increase the likelihood that these receptor regulatory events may be causally related to human heart failure. However, the final determination of the significance of the VIP and ^-receptor alterations observed in the failing human heart remains to be elucidated.
